Single-layer exfoliated reduced graphene oxide-antibody Tau sensor for detection in human serum

Abstract This study presents a novel electrochemical sensor for detection of Tau-441, an Alzheimer's disease (AD) biomarker protein. The sensor comprised a glassy carbon electrode modified by chemically exfoliated single-layer reduced graphene oxide (rGO) grafted with anti-Tau antibody. Using square wave voltammetry (SWV), the electrochemical sensor yielded a linear response to Tau-441 in the 0.08 pM-80 pM concentration range, with a low detection limit of 75 fM. The sensor has been successfully tested in the detection of Tau-441 of human serum from participants with and without AD, therefore it is shown to be an efficient and effective tool for the early diagnosis of AD.

[1]  Burak Derkus,et al.  Simultaneous quantification of Myelin Basic Protein and Tau proteins in cerebrospinal fluid and serum of Multiple Sclerosis patients using nanoimmunosensor. , 2017, Biosensors & bioelectronics.

[2]  Antonio Lobo,et al.  Dementia in western Europe: epidemiological evidence and implications for policy making , 2016, The Lancet Neurology.

[3]  Hanna Trzeciakiewicz,et al.  A protein-based electrochemical biosensor for detection of tau protein, a neurodegenerative disease biomarker. , 2014, The Analyst.

[4]  Saurabh Srivastava,et al.  Electrophoretically deposited reduced graphene oxide platform for food toxin detection. , 2013, Nanoscale.

[5]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[6]  Wenjie Luo,et al.  The complexity of tau in Alzheimer’s disease , 2019, Neuroscience Letters.

[7]  Hao Lu,et al.  Salivary biological biomarkers for Alzheimer's disease. , 2019, Archives of oral biology.

[8]  Sid O'Bryant,et al.  Developing novel blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[9]  Alison Abbott,et al.  Dementia: A problem for our age , 2011, Nature.

[10]  Daniel R. Schonhaut,et al.  Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease , 2017, NeuroImage: Clinical.

[11]  N. Jaffrezic‐Renault,et al.  A novel electrochemical aptamer-antibody sandwich assay for the detection of tau-381 in human serum. , 2018, The Analyst.

[12]  P. Snyder,et al.  Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic , 2017, Alzheimer's & Dementia.

[13]  Yikai Zhou,et al.  A novel nitrite biosensor based on single-layer graphene nanoplatelet-protein composite film. , 2011, Biosensors & bioelectronics.

[14]  K. Blennow,et al.  Alzheimer's disease , 2016, The Lancet.

[15]  A. Atri.  The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. , 2019, The Medical clinics of North America.

[16]  M. Shamsipur,et al.  An ultrasensitive sandwich-type electrochemical immunosensor for the determination of SKBR-3 breast cancer cell using rGO-TPA/FeHCFnano labeled Anti-HCT as a signal tag , 2017 .

[17]  N. Jaffrezic‐Renault,et al.  Development of a Label-Free Electrochemical Aptasensor for the Detection of Tau381 and its Preliminary Application in AD and Non-AD Patients’ Sera , 2019, Biosensors.

[18]  Michael W. Weiner,et al.  The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[19]  L. Buée,et al.  Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. , 2016, Journal of Alzheimer's disease : JAD.

[20]  Xiao Hu,et al.  Direct electrochemistry-based hydrogen peroxide biosensor formed from single-layer graphene nanoplatelet-enzyme composite film. , 2010, Talanta.

[21]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[22]  Luc Buée,et al.  Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies? , 2018, Biomedical journal.

[23]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[24]  K. Fliessbach,et al.  Tau pathology and cognitive reserve in Alzheimer's disease , 2017, Neurobiology of Aging.

[25]  Jiujun Zhang,et al.  Metal-ion bridged high conductive RGO-M-MoS2 (M = Fe3+, Co2+, Ni2+, Cu2+ and Zn2+) composite electrocatalysts for photo-assisted hydrogen evolution , 2019, Applied Catalysis B: Environmental.